WHO Classification of Tumours Editorial Board . Breast tumours [M ] . 5th ed. Lyon : International Agency for Research on Cancer , 2019 .

NCCN Clinical Prac tice Guideline in Oncology TM . Breast Cancer. 2014 National Comprehensive Cancer Network [EB/OL ] . https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1 & id=1419 https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1419 https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1419 [2021-09-02 ] .

American Joint Committee on Cancer . AJCC cancer staging handbook [M ] . 7th ed. Chicago : Springer , 2010 .

BUCHHOLZ T A , SOMERFIELD M R , GRIGGS J J , et al . Margins for breast-conserving surgery with whole-breast irradiation in stage Ⅰ and Ⅱ invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline [J ] . J Clin Oncol , 2014 , 32 ( 14 ): 1502 - 1506 . DOI: 10.1200/JCO.2014.55.1572 http://doi.org/10.1200/JCO.2014.55.1572 https://ascopubs.org/doi/10.1200/JCO.2014.55.1572 https://ascopubs.org/doi/10.1200/JCO.2014.55.1572

KUNKLER I H , WILLIAMS L J , JACK W J , et al . Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial [J ] . Lancet Oncol , 2015 , 16 ( 3 ): 266 - 273 . DOI: 10.1016/S1470-2045(14)71221-5 http://doi.org/10.1016/S1470-2045(14)71221-5 https://linkinghub.elsevier.com/retrieve/pii/S1470204514712215 https://linkinghub.elsevier.com/retrieve/pii/S1470204514712215

GIULIANO A E , MCCALL L , BEITSCH P , et al . Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial [J ] . Ann Surg , 2010 , 252 ( 3 ): 426 - 432 ; discussion 432 - 433 . DOI: 10.1097/SLA.0b013e3181f08f32 http://doi.org/10.1097/SLA.0b013e3181f08f32

DONKER M , VAN TIENHOVEN G , STRAVER M E , et al . Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial [J ] . Lancet Oncol , 2014 , 15 ( 12 ): 1303 - 1310 . DOI: 10.1016/S1470-2045(14)70460-7 http://doi.org/10.1016/S1470-2045(14)70460-7

MORAN M S , SCHNITT S J , GIULIANO A E , et al . Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer [J ] . J Clin Oncol , 2014 , 32 ( 14 ): 1507 - 1515 . DOI: 10.1200/JCO.2013.53.3935 http://doi.org/10.1200/JCO.2013.53.3935 https://ascopubs.org/doi/10.1200/JCO.2013.53.3935 https://ascopubs.org/doi/10.1200/JCO.2013.53.3935

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG . Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J ] . Lancet Oncol , 2018 , 19 ( 1 ): 27 - 39 . DOI: S1470-2045(17)30777-5 http://doi.org/S1470-2045(17)30777-5

GIANNI L , PIENKOWSKI T , IM Y H , et al . 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J ] . Lancet Oncol , 2016 , 17 ( 6 ): 791 - 800 . DOI: S1470-2045(16)00163-7 http://doi.org/S1470-2045(16)00163-7

SIKOV W M , BERRY D A , PEROU C M , et al . Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J ] . J Clin Oncol , 2015 , 33 ( 1 ): 13 - 21 .

ADAMS S , LOI S , TOPPMEYER D , et al . Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study [J ] . Ann Oncol , 2019 , 30 ( 3 ): 405 - 411 . DOI: 10.1093/annonc/mdy518 http://doi.org/10.1093/annonc/mdy518 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310762 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310762

ADAMS S , SCHMID P , RUGO H S , et al . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study [J ] . Ann Oncol , 2019 , 30 ( 3 ): 397 - 404 . DOI: 10.1093/annonc/mdy517 http://doi.org/10.1093/annonc/mdy517 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310750 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310750

GOETZ M P , TOI M , CAMPONE M , et al . MONARCH 3: abemaciclib as initial therapy for advanced breast cancer [J ] . J Clin Oncol , 2017 , 35 ( 32 ): 3638 - 3646 . DOI: 10.1200/JCO.2017.75.6155 http://doi.org/10.1200/JCO.2017.75.6155

ROBSON M , IM S A , SENKUS E , et al . Olaparib for metastatic breast cancer in patients with a germline BRCA mutation [J ] . N Engl J Med , 2017 , 377 ( 6 ): 523 - 533 . DOI: 10.1056/NEJMoa1706450 http://doi.org/10.1056/NEJMoa1706450 http://www.nejm.org/doi/10.1056/NEJMoa1706450 http://www.nejm.org/doi/10.1056/NEJMoa1706450

SLEDGE G W Jr , TOI M , NEVEN P , et al . MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy [J ] . J Clin Oncol , 2017 , 35 ( 25 ): 2875 - 2884 . DOI: 10.1200/JCO.2017.73.7585 http://doi.org/10.1200/JCO.2017.73.7585

SCHMID P , ADAMS S , RUGO H S , et al . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J ] . N Engl J Med , 2018 , 379 ( 22 ): 2108 - 2121 . DOI: 10.1056/NEJMoa1809615 http://doi.org/10.1056/NEJMoa1809615 http://www.nejm.org/doi/10.1056/NEJMoa1809615 http://www.nejm.org/doi/10.1056/NEJMoa1809615

TRIPATHY D , IM S A , COLLEONI M , et al . Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 7 ): 904 - 915 . DOI: S1470-2045(18)30292-4 http://doi.org/S1470-2045(18)30292-4

TURNER N C , SLAMON D J , RO J , et al . Overall survival with palbociclib and fulvestrant in advanced breast cancer [J ] . N Engl J Med , 2018 , 379 ( 20 ): 1926 - 1936 . DOI: 10.1056/NEJMoa1810527 http://doi.org/10.1056/NEJMoa1810527 http://www.nejm.org/doi/10.1056/NEJMoa1810527 http://www.nejm.org/doi/10.1056/NEJMoa1810527

BLOK E J , KROEP J R , MEERSHOEK-KLEIN KRANENBARG E , et al . Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05) [J ] . J Natl Cancer Inst , 2018 , 110 ( 1 ).

BURSTEIN H J , LACCHETTI C , ANDERSON H , et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update [J ] . J Clin Oncol , 2019 , 37 ( 5 ): 423 - 438 . DOI: 10.1200/JCO.18.01160 http://doi.org/10.1200/JCO.18.01160

FRANCIS P A , PAGANI O , FLEMING G F , et al . Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J ] . N Engl J Med , 2018 , 379 ( 2 ): 122 - 137 . DOI: 10.1056/NEJMoa1803164 http://doi.org/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164

GNANT M , MLINERITSCH B , STOEGER H , et al . Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group trial 12 [J ] . Ann Oncol , 2015 , 26 ( 2 ): 313 - 320 . DOI: 10.1093/annonc/mdu544 http://doi.org/10.1093/annonc/mdu544

MAMOUNAS E P , BANDOS H , LEMBERSKY B C , et al . Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2019 , 20 ( 1 ): 88 - 99 . DOI: S1470-2045(18)30621-1 http://doi.org/S1470-2045(18)30621-1

METZGER FILHO O , GIOBBIE-HURDER A , MALLON E , et al . Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial [J ] . J Clin Oncol , 2015 , 33 ( 25 ): 2772 - 2779 . DOI: 10.1200/JCO.2015.60.8133 http://doi.org/10.1200/JCO.2015.60.8133

PAN H C , GRAY R , BRAYBROOKE J , et al . 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years [J ] . N Engl J Med , 2017 , 377 ( 19 ): 1836 - 1846 . DOI: 10.1056/NEJMoa1701830 http://doi.org/10.1056/NEJMoa1701830 http://www.nejm.org/doi/10.1056/NEJMoa1701830 http://www.nejm.org/doi/10.1056/NEJMoa1701830

BLUM J L , FLYNN P J , YOTHERS G , et al . Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology) [J ] . J Clin Oncol , 2017 , 35 ( 23 ): 2647 - 2655 . DOI: 10.1200/JCO.2016.71.4147 http://doi.org/10.1200/JCO.2016.71.4147

CARDOSO F , VAN'T VEER L J , BOGAERTS J , et al . 70-gene signature as an aid to treatment decisions in early-stage breast cancer [J ] . N Engl J Med , 2016 , 375 ( 8 ): 717 - 729 . DOI: 10.1056/NEJMoa1602253 http://doi.org/10.1056/NEJMoa1602253 http://www.nejm.org/doi/10.1056/NEJMoa1602253 http://www.nejm.org/doi/10.1056/NEJMoa1602253

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J ] . Lancet , 2015 , 386 ( 10001 ): 1353 - 1361 . DOI: S0140-6736(15)60908-4 http://doi.org/S0140-6736(15)60908-4

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG . Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials [J ] . Lancet , 2019 , 393 ( 10179 ): 1440 - 1452 . DOI: 10.1016/S0140-6736(18)33137-4 http://doi.org/10.1016/S0140-6736(18)33137-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673618331374 https://linkinghub.elsevier.com/retrieve/pii/S0140673618331374

LOIBL S , WEBER K E , TIMMS K M , et al . Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto [J ] . Ann Oncol , 2018 , 29 ( 12 ): 2341 - 2347 . DOI: S0923-7534(19)34246-2 http://doi.org/S0923-7534(19)34246-2

MASUDA N , LEE S J , OHTANI S , et al . Adjuvant capecitabine for breast cancer after preoperative chemotherapy [J ] . N Engl J Med , 2017 , 376 ( 22 ): 2147 - 2159 . DOI: 10.1056/NEJMoa1612645 http://doi.org/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645

MOORE H C , UNGER J M , PHILLIPS K A , et al . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy [J ] . N Engl J Med , 2015 , 372 ( 10 ): 923 - 932 . DOI: 10.1056/NEJMoa1413204 http://doi.org/10.1056/NEJMoa1413204 http://www.nejm.org/doi/10.1056/NEJMoa1413204 http://www.nejm.org/doi/10.1056/NEJMoa1413204

NITZ U , GLUZ O , CLEMENS M , et al . West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer [J ] . J Clin Oncol , 2019 , 37 ( 10 ): 799 - 808 . DOI: 10.1200/JCO.18.00028 http://doi.org/10.1200/JCO.18.00028

SPARANO J A , GRAY R J , MAKOWER D F , et al . Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer [J ] . N Engl J Med , 2018 , 379 ( 2 ): 111 - 121 . DOI: 10.1056/NEJMoa1804710 http://doi.org/10.1056/NEJMoa1804710 http://www.nejm.org/doi/10.1056/NEJMoa1804710 http://www.nejm.org/doi/10.1056/NEJMoa1804710

PROWELL T M , BEAVER J A , PAZDUR R . Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer [J ] . N Engl J Med , 2019 , 380 ( 7 ): 612 - 615 . DOI: 10.1056/NEJMp1900079 http://doi.org/10.1056/NEJMp1900079 http://www.nejm.org/doi/10.1056/NEJMp1900079 http://www.nejm.org/doi/10.1056/NEJMp1900079

SPARANO J A , GRAY R J , RAVDIN P M , et al . Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer [J ] . N Engl J Med , 2019 , 380 ( 25 ): 2395 - 2405 . DOI: 10.1056/NEJMoa1904819 http://doi.org/10.1056/NEJMoa1904819 http://www.nejm.org/doi/10.1056/NEJMoa1904819 http://www.nejm.org/doi/10.1056/NEJMoa1904819

EARL H M , HILLER L , VALLIER A L , et al . 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial [J ] . Lancet , 2019 , 393 ( 10191 ): 2599 - 2612 . DOI: S0140-6736(19)30650-6 http://doi.org/S0140-6736(19)30650-6

MARTIN M , HOLMES F A , EJLERTSEN B , et al . Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2017 , 18 ( 12 ): 1688 - 1700 . DOI: S1470-2045(17)30717-9 http://doi.org/S1470-2045(17)30717-9

VON MINCKWITZ G , HUANG C S , MANO M S , et al . Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J ] . N Engl J Med , 2019 , 380 ( 7 ): 617 - 628 . DOI: 10.1056/NEJMoa1814017 http://doi.org/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017

VON MINCKWITZ G , PROCTER M , DE AZAMBUJA E , et al . Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J ] . N Engl J Med , 2017 , 377 ( 2 ): 122 - 131 . DOI: 10.1056/NEJMoa1703643 http://doi.org/10.1056/NEJMoa1703643 http://www.nejm.org/doi/10.1056/NEJMoa1703643 http://www.nejm.org/doi/10.1056/NEJMoa1703643

GIANNI L , PIENKOWSKI T , IM Y H , et al . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J ] . Lancet Oncol , 2012 , 13 ( 1 ): 25 - 32 . DOI: 10.1016/S1470-2045(11)70336-9 http://doi.org/10.1016/S1470-2045(11)70336-9

MA F , LI Q , CHEN S S , et al . Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [J ] . J Clin Oncol , 2017 , 35 ( 27 ): 3105 - 3112 . DOI: 10.1200/JCO.2016.69.6179 http://doi.org/10.1200/JCO.2016.69.6179

LANG G T , JIANG Y Z , SHI J X , et al . Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing [J ] . Nat Commun , 2020 , 11 ( 1 ): 5679 . DOI: 10.1038/s41467-020-19342-3 http://doi.org/10.1038/s41467-020-19342-3

JIANG Y Z , MA D , SUO C , et al . Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies [J ] . Cancer Cell , 2019 , 35 ( 3 ): 428 - 440 .e5. DOI: 10.1016/j.ccell.2019.02.001 http://doi.org/10.1016/j.ccell.2019.02.001 https://linkinghub.elsevier.com/retrieve/pii/S1535610819300960 https://linkinghub.elsevier.com/retrieve/pii/S1535610819300960

LI J J , YU K D , PANG D , et al . Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase Ⅲ trial [J ] . J Clin Oncol , 2020 , 38 ( 16 ): 1774 - 1784 . DOI: 10.1200/JCO.19.02474 http://doi.org/10.1200/JCO.19.02474 https://ascopubs.org/doi/10.1200/JCO.19.02474 https://ascopubs.org/doi/10.1200/JCO.19.02474

YU K D , YE F G , HE M , et al . Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 9 ): 1390 - 1396 . DOI: 10.1001/jamaoncol.2020.2965 http://doi.org/10.1001/jamaoncol.2020.2965 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769305 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769305

WANG X , WANG S S , HUANG H , et al . Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial [J ] . JAMA , 2021 , 325 ( 1 ): 50 - 58 . DOI: 10.1001/jama.2020.23370 http://doi.org/10.1001/jama.2020.23370 https://jamanetwork.com/journals/jama/fullarticle/2774295 https://jamanetwork.com/journals/jama/fullarticle/2774295

HU X C , ZHANG J , XU B H , et al . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet Oncol , 2015 , 16 ( 4 ): 436 - 446 . DOI: 10.1016/S1470-2045(15)70064-1 http://doi.org/10.1016/S1470-2045(15)70064-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204515700641 https://linkinghub.elsevier.com/retrieve/pii/S1470204515700641

ZHANG J , LIN Y , SUN X J , et al . Biomarker assessment of the CBCSG006 trial: a randomized phase Ⅲ trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer [J ] . Ann Oncol , 2018 , 29 ( 8 ): 1741 - 1747 . DOI: 10.1093/annonc/mdy209 http://doi.org/10.1093/annonc/mdy209 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341286 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341286

LIN M X , CHEN Y , JIN Y Z , et al . Comparative overall survival of CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone for hormone receptor-positive, HER2-negative metastatic breast cancer [J ] . J Cancer , 2020 , 11 ( 24 ): 7127 - 7136 . DOI: 10.7150/jca.48944 http://doi.org/10.7150/jca.48944 https://www.jcancer.org/v11p7127.htm https://www.jcancer.org/v11p7127.htm

FALLON M , GIUSTI R , AIELLI F , et al . Management of cancer pain in adult patients: ESMO clinical practice guidelines [J ] . Ann Oncol , 2018 , 29 ( Suppl 4 ): iv166 -iv191. DOI: 10.1093/annonc/mdy152 http://doi.org/10.1093/annonc/mdy152 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316989 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316989

ZHAO S , MA D , XIAO Y , et al . Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance [J ] . Oncologist , 2020 , 25 ( 10 ): e1481 -e1491. DOI: 10.1634/theoncologist.2019-0982 http://doi.org/10.1634/theoncologist.2019-0982 https://academic.oup.com/oncolo/article/25/10/e1481/6443719 https://academic.oup.com/oncolo/article/25/10/e1481/6443719

JIANG Y Z , LIU Y , XIAO Y , et al . Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial [J ] . Cell Res , 2021 , 31 ( 2 ): 178 - 186 . DOI: 10.1038/s41422-020-0375-9 http://doi.org/10.1038/s41422-020-0375-9

ALBABTAIN H , ALWHAIBI M , ALBURAIKAN K , et al . Quality of life and complementary and alternative medicine use among women with breast cancer [J ] . Saudi Pharm J , 2018 , 26 ( 3 ): 416 - 421 . DOI: 10.1016/j.jsps.2017.12.020 http://doi.org/10.1016/j.jsps.2017.12.020

林洪生 , 刘杰 , 张英 . 《恶性肿瘤中医诊疗指南》的内涵及其意义 [J ] . 中国肿瘤临床与康复 , 2016 , 23 ( 3 ): 257 - 260 .

LIN H S , LIU J , ZHANG Y . Connotation and significance of “Guidelines for Diagnosis and Treatment of Malignant Tumors in Traditional Chinese Medicine” [J ] . Chin J Clin Oncol Rehabil , 2016 , 23 ( 3 ): 257 - 260 .

陈前军 , 裴晓华 . 早期乳腺癌中医辨证内治专家共识 [J ] . 现代中医临床 , 2020 , 27 ( 3 ): 5 - 8 .

CHEN Q J , PEI X H . Consensus on TCM syndrome differentiation and internal therapy for early-stage breast cancer [J ] . Mod Chin Clin Med , 2020 , 27 ( 3 ): 5 - 8 .

杨雯靖 , 念家云 , 杨国旺 . 中西医结合治疗乳腺癌现状及展望 [J ] . 北京中医药 , 2020 , 39 ( 10 ): 1009 - 1013 .

YANG W J , NIAN J Y , YANG G W . Present situation and prospect of treating breast cancer with integrated traditional Chinese and western medicine [J ] . Beijing J Tradit Chin Med , 2020 , 39 ( 10 ): 1009 - 1013 .

马瑞 , 张丹 , 林从尧 . 小金丸、逍遥丸及乳癖散结胶囊治疗乳腺增生的临床观察 [J ] . 现代中西医结合杂志 , 2015 , 24 ( 2 ): 140 - 142 .

MA R , ZHANG D , LIN C Y . Clinical observation of Koganemaru, Xiaoyao Pill and Rubisanjie Capsule in the treatment of mammary hyperplasia [J ] . Mod J Integr Tradit Chin West Med , 2015 , 24 ( 2 ): 140 - 142 .

《乳腺癌HER检测指南版》编写组 . 《乳腺癌HER2检测指南(2019版)》 [J ] . 中华病理学杂志 , 2019 , 48 ( 3 ): 169 - 175 .

HER2 Detection Guidline for Breast Cancer (2019 Edition) Writing Group . HER2 guideline for breast cancer (2019 Edition) [J ] . Chin J Pathol , 2019 , 48 ( 3 ): 169 - 175 .

《乳腺癌新辅助治疗的病理诊断专家共识2020版》编写组 . 乳腺癌新辅助治疗的病理诊断专家共识(2020版) [J ] . 中华病理学杂志 , 2020 , 49 ( 4 ): 296 - 304 .

Expert Consensus on Pathological Diagnosis of Neoadjuvant Therapy for Breast Cancer (2020 Edition) Writing Group . Writing Group. Expert consensus on pathological diagnosis of neoadjuvant therapy for breast cancer (2020 Edition) [J ] . Chin J Pathol , 2020 , 49 ( 4 ): 296 - 304 .

《乳腺癌雌、孕激素受体检测指南》编写组 . 乳腺癌雌、孕激素受体检测指南 [J ] . 中华病理学杂志 , 2015 , 44 ( 4 ): 237 - 240 .

Guidelines for Detection of Estrogen and Progesterone Receptors in Breast Cancer Writing Group . Guidelines for detection of estrogen and progesterone receptors in breast cancer [J ] . Chin J Pathol , 2015 , 44 ( 4 ): 237 - 240 .

GOLDHIRSCH A , INGLE J N , GELBER R D , et al . Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 [J ] . Ann Oncol , 2009 , 20 ( 8 ): 1319 - 1329 . DOI: 10.1093/annonc/mdp322 http://doi.org/10.1093/annonc/mdp322

GOLDHIRSCH A , WOOD W C , COATES A S , et al . Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011 [J ] . Ann Oncol , 2011 , 22 ( 8 ): 1736 - 1747 . DOI: 10.1093/annonc/mdr304 http://doi.org/10.1093/annonc/mdr304 https://linkinghub.elsevier.com/retrieve/pii/S0923753419384145 https://linkinghub.elsevier.com/retrieve/pii/S0923753419384145

GOLDHIRSCH A , WINER E P , COATES A S , et al . Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2013 [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2206 - 2223 . DOI: 10.1093/annonc/mdt303 http://doi.org/10.1093/annonc/mdt303

WRIGHT M J , PARK J , FEY J V , et al . Perpendicular inked versus tangential shaved margins in breast-conserving surgery: does the method matter? [J ] . J Am Coll Surg , 2007 , 204 ( 4 ): 541 - 549 . DOI: 10.1016/j.jamcollsurg.2007.01.031 http://doi.org/10.1016/j.jamcollsurg.2007.01.031 https://journals.lww.com/00019464-200704000-00003 https://journals.lww.com/00019464-200704000-00003

ELSTON C W , ELLIS I O . Pathological prognostic factors in breast cancer.Ⅰ. The value of histological grade in breast cancer: experience from a large study with long-term follow-up [J ] . Histopathology , 2002 , 41 ( 3a ): 154 - 161 . DOI: 10.1046/j.1365-2559.2002.14892.x http://doi.org/10.1046/j.1365-2559.2002.14892.x https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2559.2002.14892.x https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2559.2002.14892.x

FRIERSON H F Jr , WOLBER R A , BEREAN K W , et al . Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma [J ] . Am J Clin Pathol , 1995 , 103 ( 2 ): 195 - 198 . DOI: 10.1093/ajcp/103.2.195 http://doi.org/10.1093/ajcp/103.2.195

HAMMOND M E , HAYES D F , DOWSETT M , et al . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J ] . Arch Pathol Lab Med , 2010 , 134 ( 6 ): 907 - 922 . DOI: 10.1043/1543-2165-134.6.907 http://doi.org/10.1043/1543-2165-134.6.907

DOWSETT M , NIELSEN T O , A’HERN R , et al . Assessment of Ki-67 in breast cancer: recommendations from the international Ki-67 in breast cancer working group [J ] . J Natl Cancer Inst , 2011 , 103 ( 22 ): 1656 - 1664 . DOI: 10.1093/jnci/djr393 http://doi.org/10.1093/jnci/djr393 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djr393 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djr393

WOLFF A C , HAMMOND M E , HICKS D G , et al . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update [J ] . J Clin Oncol , 2013 , 31 ( 31 ): 3997 - 4013 . DOI: 10.1200/JCO.2013.50.9984 http://doi.org/10.1200/JCO.2013.50.9984

SYMMANS W F , PEINTINGER F , HATZIS C , et al . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy [J ] . J Clin Oncol , 2007 , 25 ( 28 ): 4414 - 4422 . DOI: 10.1200/JCO.2007.10.6823 http://doi.org/10.1200/JCO.2007.10.6823

OGSTON K N , MILLER I D , PAYNE S , et al . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J ] . Breast , 2003 , 12 ( 5 ): 320 - 327 . DOI: 10.1016/s0960-9776(03)00106-1 http://doi.org/10.1016/s0960-9776(03)00106-1

水若鸿 , 杨文涛 . 乳腺癌Ki-67阳性指数的检测和评估 [J ] . 中华病理学杂志 , 2013 , 42 ( 6 ): 420 - 423 .

SHUI R H , YANG W T . Detection and evaluation of Ki-67 positive index in breast cancer [J ] . Chin J Pathol , 2013 , 42 ( 6 ): 420 - 423 .

LIN M X , JIN Y Z , YANG Z Y , et al . Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer [J ] . Ther Adv Med Oncol , 2021 , 13 : 17588359211022881.

ZHANG J F , LIN M X , JIN Y Z , et al . Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia [J ] . Breast Cancer Res Treat , 2020 , 182 ( 3 ): 719 - 726 . DOI: 10.1007/s10549-020-05730-2 http://doi.org/10.1007/s10549-020-05730-2

《肿瘤病理诊断规范》项目组 . 肿瘤病理诊断规范(乳腺癌) [J ] . 中华病理学杂志 2016 , 45 ( 8 ): 525 - 528 .

The project team of Tumor Pathological Diagnosis Standard . Diagnostic criteria for tumor pathology (breast cancer) [J ] . Chin J Pathol , 2016 , 45 ( 8 ): 525 - 528 .

《中国乳腺导管原位癌病理诊断共识2022版》编写组 . 中国乳腺导管原位癌病理诊断共识(2022版) [J ] . 中华病理学杂志 , 2022 , 51 ( 9 ): 812 - 818 .

The Writing Team of the Chinese Consensus on Pathological Diagnosis of Breast Ductal Carcinoma in situ (2022 Edition) . Chinese consensus on pathological diagnosis of ductal carcinoma in situ of the breast (2022 edition) [J ] . Chin J Pathol , 2022 , 51 ( 9 ): 812 - 818 .

杨昭志 , 孟晋 , 马金利 , 等 . 早期乳腺癌术后靶区勾画共识 [J ] . 中国癌症杂志 , 2019 , 29 ( 9 ): 753 - 760 .

YANG Z Z , MENG J , MA J L , et al . Early stage breast cancer postoperative target volume contouring [J ] . China Oncol , 2019 , 29 ( 9 ) 753 - 760

WOLFF A C , ELIZABETH HALE HAMMOND M , ALLISON K H , et al . Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update [J ] . J Clin Oncol , 2018 , 36 ( 20 ): 2105 - 2122 . DOI: 10.1200/JCO.2018.77.8738 http://doi.org/10.1200/JCO.2018.77.8738

WOLFF A C , SOMERFIELD M R , DOWSETT M , et al . Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update [J ] . J Clin Oncol , 2023 , 41 ( 22 ): 3867 - 3872 . DOI: 10.1200/JCO.22.02864 http://doi.org/10.1200/JCO.22.02864 https://ascopubs.org/doi/10.1200/JCO.22.02864 https://ascopubs.org/doi/10.1200/JCO.22.02864

TARANTINO P , VIALE G , PRESS M F , et al . ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer [J ] . Ann Oncol , 2023 , 34 ( 8 ): 645 - 659 . DOI: 10.1016/j.annonc.2023.05.008 http://doi.org/10.1016/j.annonc.2023.05.008

SHI F , LIANG Z , ZHANG Q , et al . The performance of one-step nucleic acid amplification assay for intraoperative detection of sentinel lymph node macrometastasis in breast cancer: an updated meta-analysis [J ] . Breast , 2018 , 39 : 39 - 45 . DOI: S0960-9776(18)30053-5 http://doi.org/S0960-9776(18)30053-5

HUXLEY N , JONES-HUGHES T , COELHO H , et al . Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer [J ] . Health Technol Assess , 2015 , 19 ( 2 ): Ⅴ - ⅩⅩⅤ .

BUNDRED J R , MICHAEL S , STUART B , et al . Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis [J ] . BMJ , 2022 , 378 : e070346 .

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .